Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02195232 · ClinicalTrials.gov registry record · Phase 2
Cancer Associated Thrombosis and Isoquercetin (CATIQ)
A Phase 2 study of Thromboembolism of Vein VTE in Colorectal Cancer and Thromboembolism of Vein in Pancreatic Cancer, sponsored by Jeffrey Zwicker, MD.
- Completed
- Registry status
- Phase 2
- Development phase
- 64
- Enrollment target
- 11
- Study locations
NCT02195232: Completed Phase 2 study of Thromboembolism of Vein VTE in Colorectal Cancer and Thromboembolism of Vein in Pancreatic Cancer, sponsored by Jeffrey Zwicker, MD.
NCT02195232 is a Phase 2 study of Thromboembolism of Vein VTE in Colorectal Cancer and Thromboembolism of Vein in Pancreatic Cancer that has completed, run by Jeffrey Zwicker, MD. The registered enrollment target is 64 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (52% lower). The trial reports 11 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02195232, a Phase 2 study of Thromboembolism of Vein VTE in Colorectal Cancer and Thromboembolism of Vein in Pancreatic Cancer, has completed, sponsored by Jeffrey Zwicker, MD.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 64 participants
- Enrollment target
- 11
- Study locations
Study Summary
This research study is evaluating a drug called isoquercetin to prevent venous thrombosis (blood clots), in participants who have pancreas, non small cell lung cancer or colorectal cancer.
Primary Outcome
D-dimer concentrations will be compared for each patient at day 0 and day 56 by a paired-t test analysis. Analysis will be performed on an intention to treat basis for patients who undergo randomization and completed the baseline and day 56 D-dimer assessments.
Conditions Studied
Interventions
- DRUG Isoquercetin
Study Locations (11)
Massachusetts
- Boston VA Healthcare System - Boston
- Beth Israel Deaconess Medical Center - Boston
- Mount Auburn Hospital - Waltham
California
- USC/Norris Comprehensive Cancer Center - Los Angeles
- VA Northern California Health Care System - Sacramento
Connecticut
- VA Connecticut Healthcare System - West Haven
District of Columbia
- Veterans Affair Medical Center - Washington D.C.
Maine
- York Hospital-Oncology Treatment Center - York Village
Missouri
- Washington University in St. Louis - St Louis
Rhode Island
- Providence VA Medical Center - Providence
Vermont
- White River Junction VA Medical Center - White River Junction
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2015-01 |
| Est. Completion | 2019-10-22 |
| Phase | Phase 2 |
What the finished NCT02195232 record still lists
NCT02195232 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 64 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (52% lower).
The record links to 3 conditions, with Thromboembolism of Vein VTE in Colorectal Cancer appearing as the primary indexed condition, and to 1 intervention - of which Isoquercetin is the first listed.
NCT02195232 lists 11 locations in 8 states (Massachusetts, California, Connecticut).
Frequently Asked Questions
What is clinical trial NCT02195232 about?
NCT02195232 is a clinical study titled "Cancer Associated Thrombosis and Isoquercetin (CATIQ)". This research study is evaluating a drug called isoquercetin to prevent venous thrombosis (blood clots), in participants who have pancreas, non small cell lung cancer or colorectal cancer.
What is the current status of trial NCT02195232?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 64 participants. The study started on 2015-01. Estimated completion is 2019-10-22.
What conditions does trial NCT02195232 study?
This clinical trial studies the following conditions: Thromboembolism of Vein VTE in Colorectal Cancer, Thromboembolism of Vein in Pancreatic Cancer, Thromboembolism of Vein in Non-small Cell Lung Cancer.
What interventions are being tested in trial NCT02195232?
The interventions under investigation include: Isoquercetin (DRUG).
Who is sponsoring clinical trial NCT02195232?
This trial is sponsored by Jeffrey Zwicker, MD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02195232 being conducted?
This trial has 11 study locations across California, Connecticut, District of Columbia, Maine, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02195232's enrollment target sits among peer trials
64 996th of 2000 higher than 992 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01853631 · 64 participants · Phase 1
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
- NCT03739502 · 64 participants · Phase 2
A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant
- NCT03739814 · 64 participants · Phase 2
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- NCT03866408 · 64 participants · Early Phase 1
Insulin Regulation of Lipolysis and Lipolysis Proteins
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia